These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 20009438

  • 21. Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome.
    Escudero-Vilaplana V, Garcia-Gonzalez X, Osorio-Prendes S, Romero-Jimenez RM, Sanjurjo-Saez M.
    J Clin Pharm Ther; 2016 Feb; 41(1):59-63. PubMed ID: 26778738
    [Abstract] [Full Text] [Related]

  • 22. [Development of acute pure red cell aplasia after deferasirox administration in two cases of myelodysplastic syndrome].
    Hayakawa F, Tomita A, Naoe T.
    Rinsho Ketsueki; 2014 Apr; 55(4):445-9. PubMed ID: 24850456
    [Abstract] [Full Text] [Related]

  • 23. Delineating parameters of iron overload in MDS patients treated with deferasirox.
    Leitch HA.
    Leuk Res; 2010 Dec; 34(12):1556-7. PubMed ID: 20719382
    [No Abstract] [Full Text] [Related]

  • 24. Acute interstitial nephritis due to deferasirox: a case report.
    Brosnahan G, Gokden N, Swaminathan S.
    Nephrol Dial Transplant; 2008 Oct; 23(10):3356-8. PubMed ID: 18653899
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Tolerability and efficacy of deferasirox in patients with transfusional iron overload: results from a German 2-year non-interventional study.
    Nolte F, Nückel H, Schmidt B, Geer T, Rubanov O, Hebart H, Jarisch A, Albrecht S, Johr C, Schumann C, Hofmann WK.
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1531-1538. PubMed ID: 29761371
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy.
    Jabbour E, Garcia-Manero G, Taher A, Kantarjian HM.
    Oncologist; 2009 May; 14(5):489-96. PubMed ID: 19365094
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
    Delforge M, Selleslag D, Triffet A, Mineur P, Bries G, Graux C, Trullemans F, MacDonald K, Abraham I, Pluymers W, Ravoet C.
    Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes.
    Jabbour E, Kantarjian HM, Koller C, Taher A.
    Cancer; 2008 Mar 01; 112(5):1089-95. PubMed ID: 18186499
    [Abstract] [Full Text] [Related]

  • 35. Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload.
    Cappellini MD, Taher A.
    Expert Opin Pharmacother; 2008 Sep 01; 9(13):2391-402. PubMed ID: 18710363
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.
    Remacha AF, Arrizabalaga B, Del Cañizo C, Sanz G, Villegas A.
    Ann Hematol; 2010 Feb 01; 89(2):147-54. PubMed ID: 19690857
    [Abstract] [Full Text] [Related]

  • 38. Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange.
    Gattermann N, Jarisch A, Schlag R, Blumenstengel K, Goebeler M, Groschek M, Losem C, Procaccianti M, Junkes A, Leismann O, Germing U.
    Eur J Haematol; 2012 Mar 01; 88(3):260-8. PubMed ID: 22023452
    [Abstract] [Full Text] [Related]

  • 39. [The role of iron metabolism in myelodysplastic syndromes].
    Finelli C, Clissa C, Stanzani M.
    Recenti Prog Med; 2014 Mar 01; 105(3):123-6. PubMed ID: 24675455
    [Abstract] [Full Text] [Related]

  • 40. Long-term efficacy and safety of deferasirox.
    Cappellini MD.
    Blood Rev; 2008 Dec 01; 22 Suppl 2():S35-41. PubMed ID: 19059055
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.